{
  "abstract": "Background: Brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone (BV-CHP) has demonstrated survival benefits over cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in patients with CD30-positive peripheral T-cell lymphoma (PTCL) in a randomized, clinical trial. However, data on the real-world effectiveness of BV-CHP in routine clinical practice remain limited.\n\nMethods: We conducted a multicenter, retrospective cohort study of patients with newly diagnosed PTCL treated at institutions within the Gifu Hematology Study Group. Patients received BV-CHP, CHOP, or cyclophosphamide, pirarubicin, vincristine, and prednisone (THP-COP) as first-line therapy. Progression-free survival (PFS), overall survival (OS), and overall response rate (ORR) were compared among the treatment groups. Exploratory subgroup analyses were performed, including analyses by bone marrow involvement at diagnosis.\n\nResults: A total of 154 patients were included: 29 received BV-CHP, 72 received CHOP, and 53 received THP-COP. Overall, no significant differences were observed in PFS, OS, or ORR among the three treatment groups. In exploratory subgroup analyses, patients with bone marrow involvement who were treated with BV-CHP (n = 4) had significantly shorter PFS than those treated with CHOP (n = 17) or THP-COP (n = 15), whereas no significant difference in OS was observed.\n\nConclusions: In this real-world multicenter cohort from the Gifu Hematology Study Group, frontline BV-CHP did not demonstrate a survival advantage over CHOP or THP-COP in unselected patients with PTCL. These findings suggest that THP-COP remains a reasonable first-line treatment option in routine clinical practice. The inferior PFS observed in patients with bone marrow involvement treated with BV-CHP should be interpreted cautiously and warrants further investigation.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 20,
  "authors": [
    {
      "name": "Nobuhiko Nakamura"
    },
    {
      "name": "Nobuhiro Kanemura"
    },
    {
      "name": "Naoki Hayase"
    },
    {
      "name": "Yuto Kaneda"
    },
    {
      "name": "Yoshikazu Ikoma"
    },
    {
      "name": "Takayuki Goto"
    },
    {
      "name": "Tomomi Suzaki"
    },
    {
      "name": "Junichi Kitagawa"
    },
    {
      "name": "Senji Kasahara"
    },
    {
      "name": "Toshiki Yamada"
    },
    {
      "name": "Michio Sawada"
    },
    {
      "name": "Kenji Fukuno"
    },
    {
      "name": "Eri Takada"
    },
    {
      "name": "Hideko Goto"
    },
    {
      "name": "Shin Lee"
    },
    {
      "name": "Kei Fujita"
    },
    {
      "name": "Tetsuji Morishita"
    },
    {
      "name": "Takeshi Hara"
    },
    {
      "name": "Hisashi Tsurumi"
    },
    {
      "name": "Masahito Shimizu"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/ceme7efcretne.bib",
  "cited_by": 0,
  "doi": "10.3960/jslrt.26008",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13759247/",
  "id": "ceme7efcretne",
  "issns": [
    "1346-4280",
    "1880-9952"
  ],
  "landing_url": "https://doi.org/10.3960/jslrt.26008",
  "language": "en",
  "licence": "CC-BY-NC-SA-4.0",
  "licence_label": "CC BY-NC-SA 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-sa/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Original Article"
    ],
    [
      "openalex",
      "2734|Lymphoma Diagnosis and Treatment"
    ]
  ],
  "openalex": "W7171701912",
  "pdf_url": "https://www.jstage.jst.go.jp/article/jslrt/advpub/0/advpub_26008/_pdf",
  "pmcid": "PMC13759247",
  "pmid": "42528231",
  "published": "2026-07-30",
  "publisher": "Japanese Society for Lymphoreticular Tissue Research",
  "ris": "https://research.draconitic.com/paper/ceme7efcretne.ris",
  "sources": [
    {
      "first_seen": "2026-11-16T12:23:55Z",
      "native_id": "PMC13759247",
      "source": "pmc",
      "url": "https://doi.org/10.3960/jslrt.26008"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2734|Lymphoma Diagnosis and Treatment",
      "subfield": "general"
    }
  ],
  "title": "Real-world comparison of brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone and anthracycline-based regimens in peripheral T-cell lymphoma: A multicenter retrospective study from the Gifu Hematology Study Group",
  "title_text": "Real-world comparison of brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone and anthracycline-based regimens in peripheral T-cell lymphoma: A multicenter retrospective study from the Gifu Hematology Study Group",
  "type": "peer-reviewed",
  "updated_at": "2026-11-16T12:23:55Z",
  "url": "https://research.draconitic.com/paper/ceme7efcretne",
  "venue": "Journal of Clinical and Experimental Hematopathology : JCEH",
  "versions": []
}